Kidney Histopathological Features in Patients After COVID-19 and SARS-CoV-2 Vaccination
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Giessen
- Enrollment
- 42
- Locations
- 1
- Primary Endpoint
- Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases
Study Overview
Brief Summary
The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.
Detailed Description
The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •being diagnosed with COVID-19 when kidney biopsy was performed
- •history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines
Exclusion Criteria
- •Patient refuses participation
Outcomes
Primary Outcomes
Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases
Time Frame: Kidney biopsy obtained during COVID-19 disease and up to 3 months after SARS-CoV-2 vaccination
Secondary Outcomes
No secondary outcomes reported